Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00003881
DRKS00003881
Completed
Phase 3

A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer - VENICE

Sanofi0 sites1,224 target enrollmentApril 30, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsProstatic NeoplasmsNeoplasm MetastasisC61Malignant neoplasm of prostate

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Prostatic NeoplasmsNeoplasm Metastasis
Sponsor
Sanofi
Enrollment
1224
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 30, 2012
End Date
April 1, 2012
Last Updated
last year
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Sanofi

Eligibility Criteria

Inclusion Criteria

  • •Histologically\- or cytologically\-confirmed prostate adenocarcinoma;
  • •\- Metastatic disease;
  • •\- Progressive disease while receiving hormonal therapy or after surgical castration;
  • •\- Effective castration.

Exclusion Criteria

  • •\- Prior cytotoxic chemotherapy for prostate cancer, except estramustine and except
  • •adjuvant/neoadjuvant treatment completed \>3 years ago;
  • •\- Prior treatment with Vascular Endothelial Growth Factor (VEGF) inhibitors or VEGF
  • •receptor inhibitors;
  • •\- Eastern Cooperative Oncology Group (ECOG) performance status \>2\.
  • •The above information is not intended to contain all considerations relevant to a
  • •patient's potential participation in a clinical trial.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney Disease
EUCTR2006-003173-27-PLAmgen Ltd334
Active, not recruiting
Not Applicable
A Multicenter, Randomized, Double-blind Study Comparing De Novo OnceMonthly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction ofAnemia in Subjects With Chronic Kidney Disease Not Receiving Dialysis
EUCTR2006-003173-27-GRAmgen Ltd540
Active, not recruiting
Phase 1
A Multicenter, Randomized, Double-blind Study Comparing De Novo Once Monthly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction of Anemia in Subjects With Chronic Kidney Disease Not Receiving DialysisAnemia in subjects with chronic kidney disease not receiving dialysisMedDRA version: 9.1 Level: LLT Classification code 10002272 Term: AnemiaMedDRA version: 9.1 Level: LLT Classification code 10064848 Term: Chronic kidney disease
EUCTR2006-003173-27-GBAmgen Ltd540
Active, not recruiting
Not Applicable
A Multicenter, Randomized, Double-blind Study Comparing De Novo OnceMonthly and Once Every 2 Week Darbepoetin alfa Dosing for the Correction ofAnemia in Subjects With Chronic Kidney Disease Not Receiving DialysisAnemia in subjects with chronic kidney disease not receiving dialysisMedDRA version: 9.1Level: LLTClassification code 10002272Term: AnemiaMedDRA version: 9.1Level: LLTClassification code 10064848Term: Chronic kidney disease
EUCTR2006-003173-27-SIAmgen Ltd540
Active, not recruiting
Not Applicable
Study Evaluating Once Monthly Darbepoetin Alfa Dosing for the Correction of Anemia in Non-dialysis Patients With Chronic Kidney DiseaseAnemia in subjects with chronic kidney disease not receiving dialysisMedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10002272Term: AnemiaSystem Organ Class: 10005329 - Blood and lymphatic system disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2006-003173-27-DEAmgen Ltd334